Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Neurocrine Biosciences Reports Third Quarter 2013 Results
Yahoo
Wednesday, October 30, 2013 - 10:35am
tags:
Neurocrine Biosciences
The Rise and Fall of a Revolutionary Drug
Motley Fool
Wednesday, October 30, 2013 - 10:34am
tags:
Vertex Pharmaceuticals, Incivek, hepatitis C
Janssen Faces 2nd Trial Over Drug’s Link to Birth Defects
Bloomberg
Wednesday, October 30, 2013 - 10:12am
tags:
Janssen, birth defects, Topamax
Update on Glaxo's Vaccine Portfolio
Yahoo/Zacks
Wednesday, October 30, 2013 - 10:09am
tags:
GSK, vaccines, Synflorix
Pernix Co-Promotes with Cumberland
Yahoo/Zacks
Wednesday, October 30, 2013 - 10:07am
tags:
Pernix, Cumberland, Omeclamox-Pak, H pylori
Teva Pharmaceuticals: Copaxone's Upcoming Expiration Continues To Depress Its Current Valuation
Seeking Alpha
Wednesday, October 30, 2013 - 10:05am
tags:
Teva, MS, multiple sclerosis, Copaxone
FDA Throws More Cold Water On Amarin's Hopes For Vascepa
Forbes
Wednesday, October 30, 2013 - 10:03am
tags:
FDA, Amarin, Vascepa
Teva CEO Levin to Step Down After Reported Board Feud
Bloomberg
Wednesday, October 30, 2013 - 10:02am
tags:
Teva, Jeremy Levin, Pharma CEOs
Dendreon Grasps for Bid as Main Drug Burns Cash: Real M&A
Bloomberg
Wednesday, October 30, 2013 - 9:52am
tags:
M&A, Dendreon
Arena's Belviq Refills Week 19
Seeking Alpha
Wednesday, October 30, 2013 - 9:51am
tags:
Arena Pharmaceuticals, Belviq, Eisai
Gilead Sciences' CEO Discusses Q3 2013 Results - Earnings Call Transcript
Yahoo/Seeking Alpha
Wednesday, October 30, 2013 - 9:46am
tags:
Gilead Sciences, earnings
MannKind announces FDA acknowledgement of NDA resubmission for Afrezza
Yahoo/Fly on the Wall
Wednesday, October 30, 2013 - 9:45am
tags:
diabetes, inhaled insulin, MannKind, FDA, Afrezza
Sanofi Profit Forecast Eases Concern After Setbacks
Bloomberg
Wednesday, October 30, 2013 - 9:42am
tags:
Sanofi, guidance
Short Sarepta: DMD Drug Prognosis Is Dismal
Seeking Alpha
Wednesday, October 30, 2013 - 9:35am
tags:
Sarepta Therapeutics, Duchenne Muscular Dystrophy, eteplirsen
Xenoport, Questcor, and NuVasive Could Be Big Movers Today
Motley Fool
Wednesday, October 30, 2013 - 9:34am
tags:
XenoPort, Questcor, NuVasive, XP23829, Pain Therapeutics, Horizant
NeoStem: Major Developments You Might Have Missed
Seeking Alpha
Wednesday, October 30, 2013 - 9:31am
tags:
NeoStem, stem cells, PCT
Pfizer Profit Gets Help From Cancer-Fighting Unit
Forbes
Tuesday, October 29, 2013 - 12:45pm
tags:
Pfizer, earnings, cancer, oncology
BMS rheumatoid arthritis drug clazakizumab causes a stir at ACR
Pharma Times, UK
Tuesday, October 29, 2013 - 12:14pm
tags:
rheumatoid arthritis, clazakizumab, Bristol-Myers Squibb
Boston Scientific reports data shows blood pressure reduction with Vessix
Yahoo/AP
Tuesday, October 29, 2013 - 12:11pm
tags:
Boston Scientific, hypertension, Vessix, devices
Moving Too Fast? Expedited Drug Approvals Raise Questions
Pharmalot
Tuesday, October 29, 2013 - 12:08pm
tags:
drug approvals, FDA

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.